EMEA-001635-PIP03-17
Key facts
| Active substance |
Tanezumab
|
| Therapeutic area |
Pain
|
| Decision number |
P/0070/2018
|
| PIP number |
EMEA-001635-PIP03-17
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
|
| Contact for public enquiries |
Pfizer Limited
Tel. + 44 1304646607 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|